A dynamical system model for tumor-immune system interaction together with a method to mimic radiation therapy are proposed. A large population of virtual patients is simulated following an ideal radiation treatment. The dependency of the results on system parameter values is studied. Conclusions for treatment optimization and patient classification are drawn from the statistic treatment of the results.
Introduction
Some approaches to cancer growth and behavior have been made in the past years. Recent techniques try to use a population dynamics model [1, 2, 3, 4] to mathematically describe the tumor behavior and its interaction with the immune system. Some of these works explain tumor behaviour under clinical treatments like cytokines [5] or radiovirotherapy [6] and properly explain the qualitative behaviors of several tumors. Even though some works had been made to describe cancer radiotherapy treatments [2] , they are but vaguely tied to clinical observations and their large number of variables and coefficients make their results hardly applicable in a clinical context. Radiotherapy and surgery are the most effective treatments for cancer, and even when surgery has a longer tradition, radiotherapy is replacing surgery for the control of many tumors [7] . Those treatments follow strict protocols that often apply fixed physical radiation doses hardly taking into account the kind of tumor or the patient immunological condition. Thus, a radiotherapy protocol might result in a very low success probability for some patients starting their treatments with a weakened immune system. In practice such a treatment will be interrupted if no results are observed, although the patient will have already received unnecessary doses of radiation.
Due to its importance and looking for an applicable method, we intend to model a radiotherapy treatment making the simplest possible assumptions. Furthermore we will make a patient classification based on their immune system strength to fight cancer and find the success probability of each patient group following a radiotherapy treatment protocol. Finally, we will use these results to assess the optimized biological effective dose (BED) or tissue effect (E) based on a given patient physical condition.
Model
In order to describe the tumor evolution, we propose a Lotka-Volterra like model based on some assumptions. Tumor cells growthẊ (as usual, a dot over a quantity represents its time derivative) depends on the current tumoral population as aX and its mass-law interaction with lymphocytes, −bXY . Lymphocytes population grows due to tumorimmune system interaction, dXY , and falls in time exponentially, − fY , due to natural cell death. Tumor secretes interleukin which produces an immune depression effect [8, 9] , and we will make the simplest asumption supposing it proportional to the tumoral cell number,−kX. The tumor is localized and there is a constant flow, u, of lymphocytes from the immune system into this region.
So, we will model tumor-immune system interaction using the known equations [5] :
The effects of radiation over any tissue are generally classified in three phases [7] . Physical phase, when radiation ionizes atoms. Chemical phase, when ionized molecules interact with other biological components of the cell. And finally, biological phase, where the damage is fixed, and unrepairable cells are signaled to die by apoptosis.
Carcinogenesis and other malignant effects, that escape to cellular control, can appear as late effects of the biological phase and, to avoid them, radiation doses need to be minimized.
We will collect all these heterogeneous effects, according to their time scale, in two groups: short and long term effects. Short term effects occur at very small time scales compared with the time scales on which model (1) runs (those times for which changes in the X and Y variables become appreciable), and so only long term effects will be taken into account in our evolution equations. Then, we are going to assume that lymphocytes die or loose their ability to attack tumor cells immediately, and that radiation dose is concentrated at an infinitesimal instant of time. At that very moment long term effects start to take place, whereas short term effects instantaneously modify the state of the system. Thus, we also assume that when a radiation dose is applied at a given instant T n , it induces a fraction B t of the tumor cells to lose their reproductive endowment and to die exponentially. The fraction of tumor cells not affected by radiation can be computed by the linear-quadratic (LQ) model [4, 10] ,
where E is known as the tissue effect, α and β are Type A and B damage coefficients [7] , and ∆ is the physical radiation dose expressed in Gy, as usual in clinical contexts. Furthermore, a fraction B l of lymphocytes is also killed by radiation, in a manner similar to (2) although having different α and β coefficients.
To include long term processes in (1), we write a new equation for non-replicating tumor cells Z [6] , taking into account that lymphocyte population is also stimulated, as pZY , due to interaction with these cells. The number of non-replicating tumor cells decays exponentially as −rZ due to natural death and also as −qZY due to the interaction with lymphocytes. Then we arrive to the systeṁ
where
T n are the time instants when radiation doses are applied and δ(T − T n ) denotes Dirac's delta centered at T n . We have supposed that lymphocytes interact in different ways with X and Z cells, although both kind of tumor cells cause the same depression over the immune system.
Equations (3) can be expressed in a dimensionless form taking the tumor duplication time τ c = 1/a (in absence of external influences) as the characteristic time, so we introduce the dimensionless time τ = T /τ c . Through
, we obtain the dimensionless system:
A linear stability analysis of the system (4) shows that tumor will vanish to L 0 = (0; σ/λ; 0) if σ/λ > 1 and will remain controlled around [5] . If the system is L 0 -stable and initial tumor size is small enough, then the radiation treatment is unnecessary, whereas if tumor size is large enough, then the treatment will take it closer to L 0 .
However for κ < σ/λ < 1, tumor will grow exponentially and radiotherapy goal will be to bring it close enough to L 0 so that immune system can get rid of the tumor. (4) and highlights region III on which this work will focus.
The chosen characteristic time and the dimensionless parameters allow us to give a very intuitive interpretation of the critical parameters of system (4). We can see σ/λ as the efficiency of immune system over tumor growth and κ as the "deficiency" of the immune system due to tumor growth. The L 1 controlled growth state will be reached only if both parameters fulfill the same condition, in other words, if σ/λ and κ are both greater or smaller than unity at the same time. Any other condition makes L 1 < 0, and even when the stable point mathematically exists, it can not be approximated from realistic initial conditions (that should remain positive along the simulation time).
It is also easy to see that radiation treatments do not change the stability conditions of our system, given that radiotherapy does not change tumor or lymphocytes growth rate, but can drive the number of both kind of cells to very small values. Although equations (4) allow for infinitesimal x values, in real systems when the number of tumor cells becomes small enough, immune system may kill them [7] . However, in other cases when a few tumor cells survive, they can cause tumor regrowth. It is known that this behavior is almost independent on tumor size and as an estimation we will assume that the closer L 0 is (in terms of the phase space of figure 1 ) to the line where it becomes an stable point, the higher will be the probability of tumor elimination by the immune system. Thus, when x becomes small enough we will take
as the probability of tumor regression. Similarly, whenever lymphocyte population becomes zero we will assume a general failure of immune system. This situation may also occur in some cases where the tumor is removed but the immune system reaches such an extreme low concentration of lymphocytes that, consequently, the patient dies.
Simulation
We can mimic different radiation treatments with equations (4) to simulate tumor evolution. To follow radiotherapy treatment in a realistic way, we apply a radiation session every workday and none in weekends. All treatments [11, 12] take 6 weeks of radiotherapy and patients are under observation until 6 months after the end of radiotherapy sessions. We generate several virtual patients under treatment taking different values for the parameter values in equations (4) and use a four step Runge-Kutta method [13] to integrate them.
To reproduce tumor evolution resembling that of a clinical case, we need to calculate the correct values of the coefficients appearing in system 1. Estimation of these coefficients was made in [14] , and following a similar procedure it would not be too hard for clinical profesionals to estimate their values. In order to accomplish an statistical study of the dependence of treatment success on the dosage, and due to the wide range of possible parameter values in equations (4), their values are drawn randomly from a log-normal distribution, to avoid negative values, but keeping the efficiency of immune system (σ/λ) always smaller than 1. Survival factors [4, 7] are also taken as random values within the interval shown in table 1. As initial conditions we have supposed, for simplicity, that the number of tumor cells is higher than the number of lymphocytes and that both populations are distributed as normal random numbers, with parameters shown in (4), taken from [14, 4, 10] .
At this point we can proceed to make statistical predictions by generating a population of "virtual patients" (characterised by their immune system and tumor parameter values) and simulating their treatment evolutions. Tables 2 and 3 show parameter values used to generate virtual patients.
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Results and clinical interpretation
We have built a database consisting of over 300000 virtual patients. We have calculated the probability of treatment success (P s ) as the fraction of patients without tumor at the end of treatment. We have represented this probability P s as a function of tissue effect, E, (see equation (2)) and efficiency of inmune system (σ/λ). In Fig 3 , a color map of P s versus E and σ/λ is represented. This allows us to classify patients based on their σ/λ-value and to assess those patients to whom, having an extremely low success probability, the application of high radiation doses would render useless. Radiotherapy is not the appropriate treatment for those patients, although it could be used as a palliative if a good balance betwen drawbacks and advantages is presumed for a specific patient. Figure 3 : P s as a function of E and σ/λ. E − curve corresponds to the minimun values of tissue effect for which P s > 0. E + curve represents the values of tissue effect for which P s reaches its maximum value, given a fixed σ/λ.
We can see that, for a given value of σ/λ, two significant values of E can be defined: E − , below which P s is very small (less than 1%), and E + , above which P s is almost constant (with less than 1% of change). Results can be fitted to the expression,
and the significant values of E computed as functions of σ/λ. These two threshold values (E − and E + ) divide the phase space (σ/λ, E) into three regions as shown in Fig  3. The success probability is negligible in region I, below E − , while it has almost its maximum value above E + , in region III . However, on the intermediate region II, as E grows, P s increases faster towards its maximum value (above the E + curve). The cofficients α and β are generally hard, but not impossible, to find, but although several values of the rate α/β are reported in the literature [7] . However this is not enough for the clinical application and at least one of them must be found (as explained also in [7] ) to proceed. Luckily, to characterize patients, we just need, among all coefficients involved in equations 3, to know the ratio u/ f , the effective amount of lymphocites without tumor effects or inmunodepression, and b/a, a measure of the effectiveness of lymphocytes over tumor growth.
To ilustrate the clinical application of this result, we are going to suppose two virtual patients with the same σ/λ = 0.5 and different tumor sensitivities. We will assume a sensitive tumor [15] with α = 0.3Gy −1 and α/β = 5Gy, and a more resistant tumor with α = 0.1Gy −1 and α/β = 10Gy, so the tumor resistance to radiation is quite different for each case.
First, let us consider the case of a sensitive tumor [15] with α = 0.3Gy −1 and α/β = 5Gy. If we apply the typical fractionated radiotherapy used in our calculations, then the biological effective dose (BED = E/α), for each radiotherapy session of 2 Gy, will be 2.8 Gy. However, this high dose value does not really increase the success probability. A patient with an immune system efficiency of σ/λ = 0.5, has his maximum healing probability for a BED value around 1.5 Gy in each radiotherapy session. Then, we must apply a physical radiation of 1.2 Gy in each radiation session and thus, avoid an useless amount of 24 Gy to be applied in the whole treatment.
However, in the case of a tumor having a higher resistance to radiation, e.g. with α = 0.1 Gy −1 and α/β = 10 Gy, the same patient with a σ/λ = 0.5, attains a maximum success probability for a BED = 4.5 Gy, and needs a physical dose of 3.4 Gy to be applied in each session. Besides, the minimum BED value is 2.2 Gy, corresponding to 1.85 Gy of physical radiation per session. Table 4 shows the optimal calculated values of physical radiation dose for the two examples of tumor with a σ/λ = 0.5.
The oncologist, should decide the amount of radiation to apply, by evaluating expression 6 to know the treatment success probability, and taking into account other clinical factors implied.
Kind of tumor
BED for ∆ = 2Gy Optimal E Optimal BED Optimal ∆ per session Sensitive tumor α = 0.3Gy α/β = 5Gy 2.8Gy 0.45 1.5Gy 1.2Gy
Strong tumor α = 0.1Gy α/β = 10Gy 2.4Gy 0.45 4.5Gy 3.4Gy Table 4 : Optimal values for two different tumors with a rate σ/λ = 0.5.
Conclusions
The proposed method, allows us to find the success probability of a fractionated radiotherapy treatment, from the patient σ/λ and the survival fraction S t of tumor cells, even if other parameters involved are unknown. This calculation provides a way to classify patients, based on their σ/λ, and to avoid the application of non effective treatments. The radiotherapy treatment must be designed for each patient taking into account his/her immunological characteristics (σ/λ) relative to the tumor. Tissue effect has to be tuned to be larger than E − , otherwise no success will be achieved, but needs not to be larger than E + , because no improvement will be obtained for larger radiation doses. Thus, in accordance with the ALARA (As Low As Reasonably Achievable) principle [16] , the physical radiation doses should be adjusted to bring E as close as possible to E + but without outranging it. This can be performed in the clinic since the value of σ/λ can be estimated for a given patient, and the values of of α and β (in expression 2) are known or feasible to find for many kinds of tumor.
